checkAd

Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20

Nachrichtenquelle: globenewswire
04.05.2021, 22:30  |  63   |   |   

Multiple pre-clinical studies indicate that Lixte’s lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments

EAST SETAUKET, NY, May 04, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the Sidoti & Company LLC Virtual Microcap Conference being held May 19-20, 2021. Lixte Founder and CEO John S. Kovach, M.D. will present on Thursday, May 20 at 12:15 p.m. ET. Investors may attend Lixte’s virtual presentation by visiting the conference registration webpage.

“During my presentation at the Sidoti conference, I will focus on the key advantages of our lead compound LB-100,” said Dr. Kovach. “At present we are not aware of any clinical competition for LB-100, and we benefit from a broad, high-value IP asset portfolio. The potential market value for our product is very large as many preclinical studies by outstanding independent investigators indicate that LB-100 appears to enhance the efficacy of chemotherapy, radiotherapy and immunotherapy.”

Lixte’s product pipeline presently includes three clinical studies and one pharmacology study of LB-100 for four of the most aggressive cancers: myelodysplastic (MDS) syndromes, advanced soft tissue sarcomas (ASTS), small cell lung cancer (SCLC), and glioblastoma multiforme (GBM). The total market for these cancer targets exceeds $5 billion.

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the “on” switches because the “off” switches, especially the master “off” switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, damaged by chemo or other cancer therapies, to continue to replicate before repairing the damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning. lixte.com

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml.

Lixte Contact:
info@lixte.com
General Phone: (631) 830-7092
Investor Phone: (888) 289-5533





0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20 Multiple pre-clinical studies indicate that Lixte’s lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments EAST SETAUKET, NY, May 04, 2021 (GLOBE NEWSWIRE) - Lixte Biotechnology Holdings, Inc. …

Nachrichten des Autors

Titel
Titel
Titel
Titel